Micro and Nanoplastics in Greenhouse Workers: Biomarkers of Exposure and Effect

February 22, 2024 updated by: Ricard Marcos

New Tools for the Detection of Micro and NanoPLastics (MNPLs) in Greenhouse Workers as a Population Highly Exposed to Plastics: Effect on Different Biomarkers of Genotoxic Effect

MNPLs effects on human health are still preliminary. Workers exposed to plastic residues are exposed constantly to MNPLs. One of these jobs corresponds to greenhouse workers, that could be considered as a population highly exposed to plastics. The objective of the research is to be able to detect MNPLs on body fluids as well as their potential genotoxic and immunological damage.

Study Overview

Detailed Description

The exponential increase in the production/use of plastic translates into a parallel increase of environmental plastic waste that is continuously degraded into MNPLs. Information on the MNPLs' effects on human health is still preliminary and, furthermore, the limitations in current methodologies prevent accurate exposure/risk assessment.

This observational study will obtain body samples of greenhouse workers and from a control group. That would allow optimizing specific biomarkers of human MNPLs exposure and the characterization of biomarkers of early effect that allows an association among the exposure to MNPLs and effects on human health.

Study Type

Observational

Enrollment (Estimated)

25

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The investigators will study adult professionals working in greenhouses in the countryside of Cartagena and Almeria. At least 25 volunteer professionals willing to participate in the study will be evaluated.

Description

Inclusion Criteria of workers exposed to plastic residues:

  • Working in an operating greenhouse for a period of 1 month or more
  • Age over 18 years old
  • Absence of chronic pathology including neoplasia
  • Absence of infectious disease at the date of sample collection and for a period of more than 2 weeks
  • Spanish residence

Inclusion Criteria of controls :

  • Age over 18 years old. Matched by age, gender, and lifestyle to the exposed group.
  • Absence of chronic pathology including neoplasia
  • Absence of infectious disease at the date of sample collection and for a period of more than 2 weeks
  • Spanish residence

Exclusion Criteria of workers exposed to plastic residues:

  • Participation in another clinical study
  • Pregnancy
  • Unsigned informed consent

Exclusion Criteria of controls:

  • Participation in another clinical study
  • Pregnancy
  • Unsigned informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control

Biomonitoring studies to detect MNPLs in biological samples and study of health effects.

Determination of MNPLs levels, genotoxic damage, and immunological effects

Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces
Greenhouse workers

Biomonitoring studies to detect MNPLs in biological samples and study of health effects.

Determination of MNPLs levels, genotoxic damage, and immunological effects

Detection of biomarkers of exposure and genotoxic effect in biological blood, urine, exhalated air condensate, and feces

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biomonitoring study to detect the presence of MNPLs in body fluids
Time Frame: Up to 1 year
Blood, buccal cells, exhalate breath condensate, feaces and urine will be collected from donors to check for the presence of micro and nanoplastics and/or derivatives
Up to 1 year
Genotoxicity effects of exposure to MNPLs
Time Frame: Up to 1 year
Blood and buccal cells will be collected from donors to check for the presence genotoxic permanent damage, assessed by the micronucleus assay
Up to 1 year
Genotoxicity effects of exposure to MNPLs
Time Frame: up to 1 year
Blood will be collected from donors to check for the presence genotoxic non-permanent damage, assessed by the comet assay
up to 1 year
Study of the effects of MNPLs on immune system
Time Frame: Up to 1 year
Blood will be collected from donors to check if the presence of micro and nanoplastics have an effect on th function of the immune system (signalling and activation) in vivo and in high-risk individuals
Up to 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Surrogate biomarkers after MNPLs exposure
Time Frame: Up to 1 year
If it is possible to correlate the presence of micro and nanoplastics with the presence of plastic derivatives in body fluids, as blood or urine, this will facilitate the detection of plastic, because tecniques to detect surrogate biomarkers as e.g. plasticizers or antioxidants are cheaper and most use than the tecnology to detect MNPLs. For that different analytical tecniques will be used.
Up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Pablo Pelegrín, Instituto Murciano de Investigación Biosanitaria (IMIB)
  • Study Chair: Juan Bernardo Cabezuelo, Hospital Clínico Universitario Virgen de Arrixaca (Murcia)
  • Study Chair: Laura Martínez, Hospital Clínico Universitario Virgen de Arrixaca (Murcia)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2024

Primary Completion (Estimated)

January 1, 2025

Study Completion (Estimated)

April 1, 2025

Study Registration Dates

First Submitted

November 30, 2021

First Submitted That Met QC Criteria

June 14, 2023

First Posted (Actual)

June 18, 2023

Study Record Updates

Last Update Posted (Estimated)

February 23, 2024

Last Update Submitted That Met QC Criteria

February 22, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2-1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammation

Clinical Trials on Biomonitoring of MNPLs in biological samples of greenhouse workers and controls

Subscribe